Filtered By:
Drug: Fortamet
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 6421 results found since Jan 2013.
Fight Aging! Newsletter, July 4th 2016
In conclusion, therefore, I can say with confidence that the future of aging research is extremely bright, both scientifically and medically. The pace of progress must now be sharply accelerated, via the injection of the funds that should for many years have been allocated at far higher a level than has actually occurred.
LATEST HEADLINES FROM FIGHT AGING!
AN INTERVIEW WITH LAURA DEMING OF THE LONGEVITY FUND
https://www.fightaging.org/archives/2016/06/an-interview-with-laura-deming-of-the-longevity-fund/
Laura Deming has worked with the SENS Research Foundation and others on the molecular biology of ...
Source: Fight Aging! - July 3, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
CONCLUSIONS: The addition of all oral glucose-lowering agents in people with type 2 diabetes and inadequate glycaemic control who are on insulin therapy has positive effects on glycaemic control and insulin requirements. The addition of sulphonylureas results in more hypoglycaemic events. Additional weight gain can only be avoided by adding metformin to insulin. Other well-known adverse effects of oral glucose-lowering agents have to be taken into account when prescribing oral glucose-lowering agents in addition to insulin therapy.
PMID: 27640062 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 17, 2016 Category: Journals (General) Authors: Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE Tags: Cochrane Database Syst Rev Source Type: research
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: There is no firm evidence that DPP-4 inhibitors or GLP-1 analogues compared mainly with placebo substantially influence the risk of T2DM and especially its associated complications in people at increased risk for the development of T2DM. Most trials did not investigate patient-important outcomes.
PMID: 28489279 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 10, 2017 Category: General Medicine Authors: Hemmingsen B, Sonne DP, Metzendorf MI, Richter B Tags: Cochrane Database Syst Rev Source Type: research
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta ‐analysis of randomised trials
ConclusionsInositol appears to regulate menstrual cycles, improve ovulation and induce metabolic changes in PCOS, however evidence is lacking for pregnancy, miscarriage or live birth. Further well‐designed multicenter trial to address this issue to provide robust evidence of benefit is warranted.This article is protected by copyright. All rights reserved.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - May 24, 2017 Category: OBGYN Authors: Jyotsna Pundir, Dimitrios Psaroudakis, Prakash Savnur, Priya Bhide, Luca Sabatini, Helena Teede, Arri Coomarasamy, Shakila Thangaratinam Tags: Systematic review Source Type: research
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
CONCLUSIONS: Inositol appears to regulate menstrual cycles, improve ovulation and induce metabolic changes in PCOS, however evidence is lacking for pregnancy, miscarriage or live birth. Further well-designed multicenter trial to address this issue to provide robust evidence of benefit is warranted. This article is protected by copyright. All rights reserved.
PMID: 28544572 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - May 24, 2017 Category: OBGYN Authors: Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, Coomarasamy A, Thangaratinam S Tags: BJOG Source Type: research
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in...
Source: Diabetologia - August 2, 2017 Category: Endocrinology Source Type: research
Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect.
PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research
Lactate Levels with Chronic Metformin Use: A Narrative Review
AbstractMetformin has been associated with lactic acidosis. Lactate levels are not commonly tested in clinical practice, and it is unclear to what extent metformin would typically increase lactate levels with chronic use. The aim of this review was to determine whether regular monitoring of the plasma lactate level would be beneficial in avoiding lactate accumulation and, ultimately, minimising the incidence of lactic acidosis in metformin-treated patients.A comprehensive search of PubMed, Embase, Web of Science, Cochrane and International Pharmaceutical Abstracts databases covering the period up to 30 May 2017 was perform...
Source: Clinical Drug Investigation - August 23, 2017 Category: Drugs & Pharmacology Source Type: research
Optimizing the Treatment of Steroid-Induced Hyperglycemia.
CONCLUSIONS: Since there are limited clinical data available to guide therapy, strategies that minimize the risk of adverse effects should be selected for the management of steroid-induced hyperglycemia. Therapies that may be safe and effective given current information include DPP-4 inhibitors, metformin, and weight-based neutral protamine Hagedorn insulin.
PMID: 28836444 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 1, 2017 Category: Drugs & Pharmacology Authors: Wallace MD, Metzger NL Tags: Ann Pharmacother Source Type: research
Fight Aging! Newsletter, October 2nd 2017
This study featured two independent experiments. The first established the safety of administering a therapeutic gene delivery vector, BNP116, created from an inactivated virus over three months, into 48 pigs without heart failure through the coronary arteries via catheterization using echocardiography. The second experiment examined the efficacy of the treatment in 13 pigs with severe heart failure induced by mitral regurgitation. Six pigs received the gene and 7 received a saline solution.
The researchers determined that the gene therapy was safe and significantly reversed heart failure by 25 percent in the left v...
Source: Fight Aging! - October 1, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 22nd 2018
In conclusion, death is a natural part of human existence, but human progress is essentially a story of overcoming undesirable natural limits. In the near future, technological progress might make it possible to stop natural biological death. Should humankind embrace such technology? Yes: Even though such technology would not be without risks, the risks are almost certainly manageable. The benefits of ending natural death, on the other hand, are immense. Death is an obstacle that is slowing down human progress. If we remove that obstacle, humankind could increase the speed of both its moral and its epistemic progress.
...
Source: Fight Aging! - January 21, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Funding More Work on Deep Learning for Drug Discovery to Treat Aging
Recently Y Combinator announced their intent to fund companies working on treatments for aging. It is one of the many signs of a growing interest in this area of development in the venture community. One of the early results appears to be more funding for computational methods of improving drug discovery, with therapies for aging as the rallying cry, after the established Insilico Medicine model. It makes sense that a primarily software-focused part of the venture community would move into a new area, biotechnology, by funding ventures that apply computational technology to the space. That says nothing about the effectiven...
Source: Fight Aging! - March 6, 2018 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Does common prescription medication affect the rate of orthodontic tooth movement? A systematic review.
Conclusions: Commonly prescribed medications may exhibit variable effects on the rate of orthodontic tooth movement. Although the quality of evidence was considered at best as low, raising reservations about the strength of the relevant recommendations, the clinician should be capable of identifying patients taking medications and should take into consideration the possible implications related to the proposed treatment.
Registration: PROSPERO (CRD42015029130).
PMID: 29522172 [PubMed - as supplied by publisher]
Source: European Journal of Orthodontics - March 6, 2018 Category: Dentistry Authors: Makrygiannakis MA, Kaklamanos EG, Athanasiou AE Tags: Eur J Orthod Source Type: research
Efficacy of metformin in the management of periodontitis: A systematic review and meta-analysis
Publication date: Available online 16 February 2018 Source:Saudi Pharmaceutical Journal Author(s): Shariq Najeeb, Muhammad Sohail Zafar, Zohaib Khurshid, Sana Zohaib, Sreenath Arekunnath Madathil, Maria Mali, Khalid Almas Periodontitis is characterized by inflammation of the periodontium and leads to loss of teeth if untreated. Although a number of surgical and pharmacological options are available for the management of periodontitis, it still affects a large proportion of population. Recently, metformin (MF), an oral hypoglycemic, has been used to treat periodontitis. The aim of this review is to systematically evaluate ...
Source: Saudi Pharmaceutical Journal - March 26, 2018 Category: Drugs & Pharmacology Source Type: research
Fight Aging! Newsletter, May 7th 2018
The objective here is a set of tests that (a) match up to the expected outcome based on human trials of mitochondrially targeted antioxidants, and (b) that anyone can run without the need to involve a physician, as that always adds significant time and expense. These tests are focused on the cardiovascular system, particularly measures influenced by vascular stiffness, and some consideration given to parameters relevant to oxidative stress and the development of atherosclerosis.
A standard blood test, with inflammatory markers.
An oxidized LDL cholesterol assessment.
Resting heart rate and blood pressure.
Heart r...
Source: Fight Aging! - May 6, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
